Privium Fund Management B.V. Increases Stock Holdings in Moderna, Inc. $MRNA

Privium Fund Management B.V. lifted its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 36.9% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 103,433 shares of the company’s stock after buying an additional 27,857 shares during the quarter. Moderna comprises about 0.6% of Privium Fund Management B.V.’s holdings, making the stock its 20th biggest holding. Privium Fund Management B.V.’s holdings in Moderna were worth $2,967,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also modified their holdings of the company. SHANDA ASSET MANAGEMENT HOLDINGS Ltd acquired a new stake in Moderna during the 1st quarter worth $28,350,000. Jacobs Levy Equity Management Inc. purchased a new position in shares of Moderna during the first quarter worth about $28,308,000. Jump Financial LLC grew its holdings in shares of Moderna by 5,590.0% during the first quarter. Jump Financial LLC now owns 902,427 shares of the company’s stock worth $25,584,000 after purchasing an additional 886,567 shares during the last quarter. Invesco Ltd. increased its position in shares of Moderna by 17.5% during the first quarter. Invesco Ltd. now owns 5,883,624 shares of the company’s stock worth $166,801,000 after purchasing an additional 877,162 shares in the last quarter. Finally, Sessa Capital IM L.P. purchased a new stake in shares of Moderna in the 1st quarter valued at about $21,066,000. Institutional investors and hedge funds own 75.33% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently issued reports on MRNA shares. Morgan Stanley upped their target price on Moderna from $31.00 to $32.00 and gave the company an “equal weight” rating in a research report on Friday, October 10th. Evercore ISI set a $32.00 price objective on Moderna in a report on Friday, August 1st. Wells Fargo & Company restated an “equal weight” rating on shares of Moderna in a research report on Sunday, July 13th. Barclays cut their target price on shares of Moderna from $40.00 to $31.00 and set an “equal weight” rating on the stock in a report on Monday, August 4th. Finally, Citigroup assumed coverage on shares of Moderna in a research note on Friday, August 1st. They set a “neutral” rating and a $40.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, twelve have issued a Hold rating and five have assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $39.93.

Moderna Price Performance

Moderna stock opened at $27.24 on Tuesday. The business has a 50 day simple moving average of $25.94 and a 200-day simple moving average of $27.11. Moderna, Inc. has a 12 month low of $23.15 and a 12 month high of $57.69. The stock has a market capitalization of $10.64 billion, a PE ratio of -3.62 and a beta of 2.01.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings data on Friday, August 1st. The company reported ($2.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.99) by $0.86. The company had revenue of $142.00 million for the quarter, compared to analysts’ expectations of $116.26 million. Moderna had a negative net margin of 94.31% and a negative return on equity of 25.96%. Moderna’s revenue was down 41.1% compared to the same quarter last year. During the same period in the previous year, the company posted ($3.33) EPS. Moderna has set its FY 2025 guidance at EPS. As a group, equities research analysts anticipate that Moderna, Inc. will post -9.61 EPS for the current year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.